Benzinga | Oct 1, 2021 08:20AM EDT

ALX Oncology Announces 4 Abstracts Accepted For Presentation At Society For Immunotherapy Of Cancer 36th Annual Meeting On Nov. 10-14

ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company"), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced that four abstracts have been accepted for presentation at the SITC 36th Annual Meeting in Washington D.C. from November 10 --14, 2021. The abstracts, which will be presented in a poster session, include new clinical data from ASPEN-01, the ongoing Phase 1b study of evorpacept (also known as ALX148) in patients with head and neck squamous cell carcinoma and with gastric/gastroesophageal cancer, and clinical trial in progress presentations on ASPEN-03 and ASPEN-04, our Phase 2 head and neck cancer studies in collaboration with Merck. In addition, preclinical data will be presented on ALTA-002, a first-in-class SIRP?-directed TLR9 agonist antibody conjugate, which is being developed in collaboration with Tallac Therapeutics.



Poster Presentation Details

Title: Evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with head and neck squamous cell carcinoma (HNSCC) and with gastric/gastroesophageal cancer (GC); ASPEN-01 (Abstract 498)

Presentation Time: November 12 -- 14, 2021, 7:00am -- 5:00pm ET

Location: Poster Hall

Title: A phase 2 study of evorpacept (ALX148) in combination with pembrolizumab in patients with advanced head and neck squamous cell carcinoma (HNSCC); ASPEN-03 (Abstract 439)

Presentation Time: November 12 -- 14, 2021, 7:00am -- 5:00pm ET

Location: Poster Hall

Title: A phase 2 study of evorpacept (ALX148) in combination with pembrolizumab and chemotherapy in patients with advanced head and neck squamous cell carcinoma (HNSCC); ASPEN-04 (Abstract 433)

Presentation Time: November 12 -- 14, 2021, 7:00am -- 5:00pm ET

Location: Poster Hall

Title: ALTA-002, a SIRP?-directed TLR9 agonist antibody conjugate activates myeloid cells and promotes anti-tumor immunity (Abstract 780)

Presentation Time: November 12 -- 14, 2021, 7:00am -- 5:00pm ET

Location: Poster Hall